Welcome to our dedicated page for Cardinal Health news (Ticker: CAH), a resource for investors and traders seeking the latest updates and insights on Cardinal Health stock.
Cardinal Health, Inc. (NYSE: CAH) is a global leader in integrated healthcare services and products. With nearly 100 years of experience, the company stands as a pillar in the healthcare industry, ranking among the top 25 on the Fortune 500 list. Cardinal Health offers a comprehensive suite of services that cater to hospital systems, pharmacies, ambulatory surgery centers, clinical laboratories, and physician offices worldwide.
Operating through two main segments—Pharmaceuticals and Medical—Cardinal Health provides clinically-proven medical products and pharmaceuticals, alongside cost-effective solutions that enhance supply chain efficiency. The company is a major distributor of branded, generic, and specialty pharmaceutical products to a wide array of clients, including retail chains, independent pharmacies, hospital networks, and healthcare providers.
Recently, Cardinal Health reported strong financial results for Q2 FY2024, with a 12% increase in revenue to $57.4 billion. The company also saw significant growth in both its Pharmaceutical and Medical segments, driven by robust sales of brand and specialty pharmaceuticals, as well as improvements in at-Home Solutions and Global Medical Products and Distribution. CEO Jason Hollar highlighted the company's operational execution and strategic priorities, which include tech-enabled specialty acquisitions and a focus on supply chain resiliency.
Cardinal Health is also committed to sustainability and corporate responsibility. The company recently released its Fiscal 2023 Environmental, Social and Governance (ESG) Report, emphasizing long-term value creation through sustainable practices. The company has received approval from the Science Based Targets initiative (SBTi) for its ambitious greenhouse gas (GHG) emissions reduction targets. By FY2023, Cardinal Health had already reduced its Scope 1 and 2 emissions by 13% from a FY2019 base year.
In terms of infrastructure, Cardinal Health is expanding its logistics capabilities. The company has commenced construction on a new 350,000 square-foot Consumer Health Logistics Center in Columbus, Ohio, designed to support the distribution of over-the-counter consumer health products. This facility, expected to be operational by Summer 2025, will create approximately 100 new jobs and enhance Cardinal Health's supply chain agility.
Despite challenges such as the non-renewal of its pharmaceutical distribution contracts with OptumRx, Cardinal Health remains resilient. The company reaffirmed its fiscal 2024 non-GAAP diluted EPS guidance and is confident in its long-term growth targets.
For more information, visit cardinalhealth.com and follow @cardinalhealth on Twitter.
On April 17, 2023, Cardinal Health (NYSE: CAH) announced the opening of two new distribution centers in Central Ohio, marking a significant investment in its Medical Segment. These facilities, located in Groveport and Grove City, span over 782,000 square feet and are designed to support the company's U.S. Medical Products and Distribution (USMPD) and at-Home Solutions businesses. This expansion is part of Cardinal Health's multi-year warehousing modernization plan, aimed at improving service and creating jobs in the local economy. Equipped with advanced warehousing management technology, including robotics and automated fulfillment systems, the centers will enhance operational efficiency while bolstering the company's distribution network.
Cardinal Health (NYSE: CAH) will announce its third-quarter financial results for fiscal year 2023 on May 4, prior to market opening. An accompanying webcast discussing these results is scheduled for 8:30 a.m. Eastern. The company, a global distributor of pharmaceuticals and medical products, operates in over 30 countries with approximately 46,500 employees. It has a robust online platform for investor relations where the webcast and presentation slides will be available for 12 months.
Swisslog announced that Cardinal Health (NYSE: CAH) will implement its AutoStore solution at a new distribution center in Grove City, Ohio. This initiative aims to boost warehouse capacity amid rapid growth in Cardinal Health's at-Home Solutions division. The AutoStore system features 31,844 storage bins, enabling efficient management of 14,154 SKUs, ultimately enhancing speed and reducing human error in order fulfillment. This marks Cardinal Health's first use of AutoStore, reflecting a commitment to modernizing operations and addressing labor shortages. The collaboration emphasizes optimizing supply chain resilience and enhancing customer service.
On March 6, 2023, Cardinal Health (NYSE:CAH) announced a collaboration with Signify Health (NYSE:SGFY) to provide in-home clinical and medication management services via its Outcomes™ business. This initiative aims to reduce healthcare costs and address medication adherence issues for over 2.3 million members across the nation. Leveraging Signify Health's network of 11,000+ clinicians and the OutcomesOne™ platform, the service intends to enhance coordinated care, focusing initially on Medicare Advantage members. The collaboration may expand to additional services, such as population health programs.
Cardinal Health (NYSE: CAH) published its 2023 Biosimilars Report on February 22, 2023, which examines provider perceptions and trends in the biosimilars market. The report shows a significant increase in familiarity with biosimilars, particularly among rheumatologists (76%) and gastroenterologists (81%). It highlights the potential for up to 10 new Humira™ biosimilars launching in 2023, and discusses the impact of the Inflation Reduction Act and the Enhancing Oncology Model on market growth. The report aims to address challenges and opportunities in the adoption of biosimilars, ensuring equitable access to essential treatments.
Cardinal Health (NYSE: CAH) announced a quarterly dividend of
Cardinal Health (NYSE: CAH) reported a 13% revenue increase to $51.5 billion for Q2 FY23. However, it faced a GAAP operating loss of $119 million, largely due to a non-cash goodwill impairment of $709 million. Non-GAAP operating earnings remained stable at $467 million, leading to a 4% increase in non-GAAP diluted EPS, now at $1.32. The company raised its fiscal year 2023 non-GAAP EPS guidance to $5.20-$5.50. The Pharmaceutical segment saw a 15% revenue increase to $47.7 billion, while the Medical segment reported a 7% decline in revenue.
Cardinal Health (CAH) and Palantir Technologies (PLTR) have announced a strategic partnership aimed at enhancing pharmaceutical purchasing decision support for health systems and hospitals. The collaboration will utilize Palantir's Foundry platform to integrate AI and machine learning, combining clinical and purchasing data to optimize supply chain management. The solution aims to address rising drug expenses and inventory challenges, providing real-time insights to improve efficiency and access to medications. This partnership reflects Cardinal Health’s proactive approach to mitigating supply chain uncertainties in healthcare.
Cardinal Health (NYSE: CAH) is set to release its second-quarter financial results for fiscal year 2023 on February 2, prior to market opening. A webcast will begin at 8:30 a.m. Eastern to discuss these results. Cardinal Health, with over 46,500 employees globally, operates in more than 30 countries, providing essential health care services and solutions.